- Home
- KPTI vs ARMP Comparison
KPTI vs ARMP Comparison
Compare KPTI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- ARMP
- Stock Information
- Founded
- KPTI 2008
- ARMP N/A
- Country
- KPTI United States
- ARMP United States
- Employees
- KPTI N/A
- ARMP N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KPTI Health Care
- ARMP Health Care
- Exchange
- KPTI Nasdaq
- ARMP Nasdaq
- Market Cap
- KPTI 44.5M
- ARMP 104.3M
- IPO Year
- KPTI 2013
- ARMP N/A
- Fundamental
- Price
- KPTI $5.73
- ARMP $2.96
- Analyst Decision
- KPTI Buy
- ARMP Strong Buy
- Analyst Count
- KPTI 6
- ARMP 1
- Target Price
- KPTI $39.80
- ARMP $9.00
- AVG Volume (30 Days)
- KPTI 85.0K
- ARMP 11.6K
- Earning Date
- KPTI 11-04-2025
- ARMP 11-12-2025
- Dividend Yield
- KPTI N/A
- ARMP N/A
- EPS Growth
- KPTI N/A
- ARMP N/A
- EPS
- KPTI N/A
- ARMP N/A
- Revenue
- KPTI $137,269,000.00
- ARMP $6,868,000.00
- Revenue This Year
- KPTI $3.40
- ARMP $8.43
- Revenue Next Year
- KPTI $9.69
- ARMP N/A
- P/E Ratio
- KPTI N/A
- ARMP N/A
- Revenue Growth
- KPTI N/A
- ARMP 84.67
- 52 Week Low
- KPTI $3.51
- ARMP $0.90
- 52 Week High
- KPTI $16.95
- ARMP $3.14
- Technical
- Relative Strength Index (RSI)
- KPTI 45.17
- ARMP 60.37
- Support Level
- KPTI $6.15
- ARMP $2.79
- Resistance Level
- KPTI $6.85
- ARMP $2.99
- Average True Range (ATR)
- KPTI 0.51
- ARMP 0.15
- MACD
- KPTI -0.18
- ARMP 0.00
- Stochastic Oscillator
- KPTI 2.45
- ARMP 75.68
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.